Physician profile
Volkan O Taskin
NPI 1568412492
$2,587.05
in general payments reported to CMS, 2019-2025
21 companies · $499 in 2025
The $499 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $222 · 2021: $301 · 2022: $27.91 · 2023: $646 · 2024: $407 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.35 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Micro-Tech Endoscopy USA, INC. | $354.02 | 2021-2025 | Lesion Hunter, Sureclip |
| Janssen Biotech, INC. | $221.48 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.10 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $215.60 | 2019-2024 | Entyvio |
| Pfizer INC. | $159.07 | 2019-2025 | |
| Ardelyx, INC. | $120.55 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $120.09 | 2023-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $115.47 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $49.17 | 2023-2024 | Voquezna |
| Gilead Sciences, INC. | $41.86 | 2024 | |
| Shionogi INC | $39.19 | 2019 | |
| Novo Nordisk INC | $33.53 | 2025 | Wegovy |
| Boston Scientific Corporation | $26.51 | 2020-2022 | |
| Celgene Corporation | $22.25 | 2023 | Zeposia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $19.80 | 2023 | |
| Celltrion USA INC. | $18.83 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $14.81 | 2023 | Suflave, Sutab |
| Amgen INC. | $13.80 | 2025 | Uplizna |
| Shire North American Group INC | $12.83 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Volkan Taskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.